Article Information
History
- September 8, 2021.
Article Versions
- You are currently viewing Version 1 of this article (September 8, 2021 - 11:37).
- View Version 2, the most recent version of this article.
Copyright
The copyright holder for this preprint is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. All rights reserved. No reuse allowed without permission.
Author Information
- Manon Venet1,*,
- Margarida Sa Ribeiro1,*,
- Elodie Décembre1,*,
- Alicia Bellomo1,*,
- Garima Joshi1,
- Marine Villard1,
- David Cluet2,
- Magali Perret1,
- Rémi Pescamona1,
- Helena Paidassi1,
- Thierry Walzer1,
- Omran Allatif1,
- Alexandre Belot1,
- Sophie Assant1,
- Emiliano Ricci2 and
- Marlène Dreux1,$
- 1CIRI, Inserm, U1111, Université Claude Bernard Lyon 1, CNRS, UMR5308, École Normale Supérieure de Lyon, Univ Lyon, F-69007, LYON, France
- 2Laboratory of Biology and Modeling of the Cell, Université de Lyon, ENS de Lyon, Université Claude Bernard, CNRS UMR 5239, Inserm U1293, Lyon, France.
- ↵$Corresponding author/lead contact; email: marlene.dreux{at}ens-lyon.fr, Tel.: + +33 426 23 38 34.
Posted September 08, 2021.
SARS-CoV-2 infected cells trigger an acute antiviral response mediated by Plasmacytoid dendritic cells in mild but not severe COVID-19 patients
